Cellular senescence is a stable state of proliferative arrest that provides a barrier against malignant transformation and contributes to the antitumor activity of certain chemotherapies. Unexpectedly, we found that the expression of proto-oncogene PIM-1, whichcanpromotetumorigenesis,isinducedattranscriptionallevel during senescence. Inhibition of PIM-1 alleviated both replicative and oncogene-induced senescence. Conversely, ectopic expression of PIM-1 resulted in premature senescence. We also revealed that PIM-1 interacts with and phosphorylates heterochromatin protein 1c (HP1c) on Ser93. This PIM-1-mediated HP1c phosphorylation enhanced HP1c's capacity to bind to H3K9me3, resulting in heterochromatin formation and suppression of proliferative genes, such as CCNA2 and PCNA. Analysis of the mechanism underlying the upregulation of PIM-1 expression during senescence demonstrated that IL-6, a critical regulator of cellular senescence, is responsible for PIM-1 induction. Our study demonstrated that PIM-1 is a key component of the senescence machinery that contributes to heterochromatin formation. More importantly, we demonstrated that PIM-1 is also a direct target of IL-6/STAT3 signaling and mediates cytokine-induced cellular senescence.
Introduction
Senescence was initially described as a stable cell proliferation arrest resulting from the progression of primary human fibroblasts through a finite number of populations doubling in vitro (Hayflick, 1965) . However, the definition of senescence has since been broadened, stating that DNA damage and cellular stress, caused by expression of certain oncogenes, unscheduled DNA replication, oxidative stress, or dysfunctional telomeres, can both induce cellular senescence (Nishiyama et al., 1999; Collado et al., 2007) . Senescence is an important tumor suppression mechanism that restrains the proliferation of cells harboring activated oncogenes (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005) . Also, by depleting renewable stem cell populations, senescence is thought to contribute to tissue aging of many multicellular adult animals (Janzen et al., 2006; Krishnamurthy et al., 2006; Molofsky et al., 2006) .
Previous studies have proposed that the irreversibility of the senescence arrest is tightly associated with particular chromatin architecture in senescent cells, called senescence-associated heterochromatin foci (SAHF) (Narita et al., 2003; Adams, 2007) . Although not all cells exhibit such dramatic heterochromatinization, some degree of heterochromatinization appears to be a general feature of senescence in various cell types from several species (Braig et al., 2005; Denoyelle et al., 2006; Herbig et al., 2006) . SAHF associates with transcriptional silence and coincides with the recruitment of heterochromatin proteins, such as methylated lysine nine of histone H3 (H3K9Me), heterochromatin protein 1 (HP1) and histone variant macroH2A (Narita et al., 2003; Zhang et al., 2005) , and some other proteins that are less typically linked to heterochromatin, such as high-mobility group A (HMGA) proteins (Funayama et al., 2006; Narita et al., 2006) . Formation of SAHF in human is driven by a complex of histone chaperones, including histone repressor A (HIRA) and antisilencing function 1a (ASF1a) that play an evolutionarily conserved role in heterochromatin formation through plants, yeast, and other mammals (Zhang et al., 2005) . Proliferationpromoting genes, such as E2F-targeting gene CLNA, are recruited into SAHF, resulting in an irreversibly silence of gene expression (Narita et al., 2006) . Consequently, heterochromatinization appears to be important for senescence-associated tumor suppression (Narita et al., 2006) .
PIM-1 is a proto-oncogene, encoding a serine/threonine protein kinase that regulates cell proliferation and growth. Overexpression of PIM-1 leads to tumor formation in mice, while complete PIM-1 knockout has no observable phenotype. PIM-1 expression in normal tissues is nearly undetectable. However, in hematopoietic malignancies and in many solid tumors, increased PIM-1 expression has been shown to correlate with the stage of disease (Nawijn et al., 2011) . Mechanism analysis showed that PIM-1 contributes to cancer development by phosphorylating multiple target substrates that are tightly related to cells proliferation and anti-apoptosis (Bachmann & Moroy, 2005) . Oncogenic characteristic of PIM-1 makes it an attractive target for cancer therapy (Bachmann & Moroy, 2005; Magnuson et al., 2010; Nawijn et al., 2011) .
In this study, we demonstrated that Pim1 acts as a positive regulator of cellular senescence, which implies that Pim1 likely has characteristics of tumor suppressor. Significantly, we demonstrated that PIM-1 is a direct target of IL-6/STAT3 signaling and mediates cytokine-induced cellular senescence.
RasV12 and H 2 O 2 -induced premature senescence (Fig. 1A,B) . By comparing PIM-1 expression with senescence markers in RasV12-induced senescence, we found that the induction of PIM-1 expression occurred when cells just entered senescence (Fig. 1C) . There was no increase in PIM-1 expression in quiescent cells (Fig. 1D) , suggesting that the increase in PIM-1 expression is associated with senescence rather than with cell cycle arrest. Similar results were obtained in another HDF cell, WI-38 ( Fig. S1A-C) , suggesting that PIM-1 up-regulation is not unique to 2BS senescence. We did not observe significant change in PIM1 or p16 expression in control group without RasV12 (Fig. S1D ).
PIM-1 depletion delays cellular senescence
To investigate whether PIM-1 is causally involved in replicative senescence, we used two independent validated short hairpin (shRNA) targeting PIM-1.
Cells at PD30 were transduced with these shRNA-expressing lentiviruses, selected for proviral integration, and plated at equal densities. As shown in Fig. 2A , both shRNAs caused a 75% reduction of PIM-1 expression as judged by western blot. Depletion of PIM-1 with either shRNA delayed senescence in 2BS cells without cell immortalization (Fig. 2B ).
Next, we tested whether knockdown of PIM-1 influences RasV12-induced premature senescence. PIM-1 was knocked down by two shRNAs, as described above, while senescence was induced by activated RasV12. A cell proliferation assay showed that PIM-1 depletion delays RasV12-induced cellular senescence (Fig. 2C) . Similar results were achieved with two independent shRNAs (shPIM-1#1 and shPIM-1#2) (Fig. 2C) . The percentage of cells incorporating BrdU also increased upon knockdown of PIM-1 as measured on day 5 after drug selection (Fig. 2D) . Furthermore, PIM-1 knockdown resulted in a reduced percentage of cells with senescence-associated b-galactosidase (SA-b-gal) staining ( SAHF formation (Fig. 2F) , two well-known markers of cellular senescence. These data indicate that PIM-1 is associated with cells senescence. Similar results were observed following transfection of controls and shPIM-1s into BJ fibroblasts infected with a retrovirus-encoding H-RasV12 (Fig S3B) .
To complement the findings with PIM-1shRNAs, we then investigated whether overexpression of PIM-1 would induce premature senescence. Early passage 2BS human diploid fibroblasts (PD20) were infected with pBABE-puro (Ctrl), retrovirus vector expressing wild-type PIM-1 (wtPIM-1), or kinase-dead PIM-1 mutant (K67M). Cells overexpressing wtPIM-1 showed proliferation arrest (Fig. S2A ) and reduced BrdU incorporation (Fig. S2B) . PIM-1 also induced characteristic features of senescence, such as ß-gal activity and SAHF formation (Fig. S2C,D) . Previous study suggested that p53 plays an important role in PIM-1's effect on the cell cycle (Zemskova et al., 2010) . PIM-1 has also been shown to mediate neuronal death upstream of Cdc25A and Cdk/Rb/E2F (Zhang et al., 2010) . Here, we found that PIM-1 overexpression increased p53, p21, p15, and p16 expression combined with decreased Rb phosphorylation levels, indicating an elevated senescence (Fig. S2E) . In contrast, cells infected by retrovirus expressing K67M did not display senescent phenotype, suggesting that PIM-1 induction of senescence is dependent on its kinase activity. Similar results were obtained following infection of BJ fibroblast with PIM-1-expressing retrovirus (Fig. S2E) .
Because DNA damage signaling pathway acts as a critical mediator in oncogenes-induced senescence and p53, an important regulator of senescence pathway, increases in premature senescence, we speculated that this pathway also contributes to oncogene PIM-1-induced senescence. Indeed, BJ fibroblasts that senesced in response to PIM-1-accumulated DNA damage foci, which judged by cH2AX immunofluorescence staining and phosphorylated active form of ATM, indicating that aberrant oncogene activation induces a DNA damage signaling response (Fig. 2G,  H) . Depletion of ATM with an already validated shRNA (shATM) led to reduced p53 accumulation compared to control hairpin, confirming that p53 induction results from activation of DNA damage signaling (Fig S3A) . To further explore the role of DNA repair pathway in PIM-1-mediated cell cycle arrest, we analyzed the effects of PIM-1 in BJ fibroblasts in which ATM, p53, or p-Rb functions were disrupted using shRNA, HPV E6, and E7 proteins, respectively (Fig. 2I) . The shATM, E6, or E7 alone did not bypass the senescent response to PIM-1 in BJ fibroblasts (Fig. 2I) . However, co-expressing both E6 and E7 did circumvent PIM-1-induced senescence (Fig. 2I) . Similarly, combining shATM with E7 but not with E6 also blocked PIM-1-induced senescence (Fig. 2I ). These data clearly indicated the importance of DNA damage signaling pathway as well as the Rb pathway in establishing the PIM-1-induced arrest in human cells.
PIM-1 knockdown diminishes the DNA damage response of cells to RasV12
Because PIM-1 is a downstream target of active RasV12, we next investigated whether PIM-1 modulates RasV12-induced DNA damage response. To this end, we exposed BJ cells infected with a control or shPIM-1 to RasV12. PIM-1 knockdown led to decreased levels of cH2AX, phosphorylated ATM, and p53 in RasV12-induced senescent cells (Fig.S4A) . In contrast to PIM-1-induced senescence, RasV12-induced senescence is more complex and cannot be entirely rescued with E6 and E7. Co-expression of RasV12 with shPIM-1 and E7 or shPIM-1 and E6 did not prevent cells senescence. By comparing the effect of E6, E7, and shPIM-1 co-expressing, separately, on RasV12-induced senescence, we found that shPIM-1/E6 and shPIM-1/E7 were inferior to E6/E7 in delaying RasV12-induced senescence (Fig.S4B) , suggesting that PIM-1 only partly contributes to Ras-induced DNA damage.
PIM-1 interacts with and phosphorylates HP1c in senescent cells
It has been shown that HP1c, which plays an important role in heterochromatin formation, acts as target protein of PIM-1, and we hypothesized that besides of effecting DNA damage response, PIM-1 also can potentially affect heterochromatin formation by interacting with and phosphorylating HP1c protein. At first, we tested whether there is a physical interaction between PIM-1 and HP1c in oncogene-induced senescence (OIS). To this end, we carried out immunoprecipitation (IP) followed by western blot assay using nuclear extracts of senescent cells. As shown in Fig. 3A , IP with anti-PIM-1 antibody successfully pulled down HP1c, while reciprocal experiment using anti-HP1c antibody validated the interaction between PIM-1 and HP1c in senescent cells.
Because the PIM-1-mediated phosphorylation site in HP1c has never been identified, we examined which amino acid residue in HP1c is phosphorylated by PIM-1. In human HP1c, a putative PIM-1 consensus sequence is located in the amino acid sequence from 90 to 98, 90 KRKSLSDSE 98 . To identify the residue that is phosphorylated by PIM-1, each of the serine residues in this sequence was mutated to alanine to generate HP1c (S93A), HP1c (S95A), and HP1c (S97A). GST-tagged wildtype HP1c and mutant HP1c were expressed and purified from E. coli and were incubated with recombinant PIM-1 (rPIM-1) and [c-32 P] ATP in vitro. Phosphorylation of HP1c was evidently blocked by the S93A mutation ( Fig. 3B ). In contrast, the S95A and S97A mutations had no effect on HP1c phosphorylation (Fig. 3B ). These findings suggest that PIM-1 phosphorylates HP1c on serine 93, which is consistent with the observation that HP1c is phosphorylated on serine 93 in senescent cells (Zhang et al., 2007) . For in vivo analysis, an affinity-purified antibody specific to the phosphor-peptide KRKpSLSDSE was generated. This antibody specifically recognized the recombinant HP1c isoform only after phosphorylation in a PIM-1-dependent manner (Fig. S5 ). Figure 3 (C) showed that the pHP1cS93 level clearly increased in RasV12-induced senescent cells compared with the control cells. In addition, ectopically expressing PIM-1-induced cell senescence accompanied by an elevated level of pHP1cS93 (Fig. 3E ). To further demonstrate that HP1c phosphorylation stems from PIM-1 activation, PIM-1 was knocked down by two shRNAs. As shown in Fig. 3D , PIM-1 knockdown decreased the pHP1cS93 level in RasV12-induced senescent cells. A specific PIM-1 inhibitor resulted in a similar inhibition of HP1c phosphorylation (Fig. 3D) . The PIM-1 phosphorylation site overlaps with a previously reported PKA phosphorylation site in immortal and transformed cells (Lomberk et al., 2006) . It seems unlikely that phosphorylation of HP1c on this residue resulted from PKA in senescent cells, as the specific PKA inhibitor, H89, did not change the pHP1cS93 level (Fig. 3D) . Furthermore, PKA activity is decreased in senescent cells (Fig. S6) . Together, these data indicate that PIM-1 directly phosphorylates HP1c on Ser93 in senescent cells.
PIM-1-induced HP1c phosphorylation on Ser93 promotes heterochromatin formation in OIS
We further investigated the impact of PIM-1-induced Ser93 phosphorylation on HP1c functions. Two mutants were generated by altering Ser93 in HP1c to Ala or Glu (expected to preclude or mimic phosphorylation, respectively). EGFP-tagged HP1c (wild-type), HP1c (S93A) mutant, and HP1c (S93E) mutant were ectopically expressed in 2BS fibroblasts, followed by RasV12-induced senescence. Without RasV12, expression of HP1c mutants did not affect SAHF nor senescence levels (data not shown). After RasV12-induced senescence, HP1c (wild-type) and HP1c (S93E) mutant were distributed as large foci and colocalized with H3K9me3, a heterochromatic marker, whereas HP1c (S93A) mutant was diffusely distributed throughout the nucleus in senescent cells (Fig. 4A) . Consistent with this result, GST-tagged HP1c (wild-type) and mutant wild-type HP1c (S93E) effectively interacted with histone H3 and H3K9me3 in senescent cells, while mutant GST-HP1c (S93A) did not (Fig. 4B) . Furthermore, an in vitro experiment demonstrated that phosphorylation of HP1c on Ser93 by rPIM-1 promoted it to bind to a biotinylated H3K9me2 peptide, whereas its S93A mutant did not have this effect (Fig. 4C ). These data suggest that Ser93 phosphorylation enhances the capacity of HP1c to bind to H3K9me3.
It has been shown that HP1c associates with suppression of the CCNA2 and proliferating cell nuclear antigen (PCNA) promoters in senescent cells through a heterochromatin mechanism (Narita et al., 2003) . We examined whether it is the phosphorylated form of HP1c (pHP1cS93) that occupies these two genes' promoters. A chromatin immunoprecipitation (ChIP) with anti-pHP1cS93 antibody revealed that HP1c was enriched on the promoter sequence of CCNA2 and PCNA genes in senescent 2BS cells (Fig. 4D) . Consistently, senescent cells with PIM-1 knockdown displayed a decreased pHP1cS93 levels on these promoters (Fig. 4D ) and increased CCNA2 and PCNA expressions (Fig. 4E ). In addition, phosphorylated form of HP1c (pHP1cS93) that occupies these two genes' promoters still occurred in BJ fibroblasts (Fig.  S7 ). This suggests that pHP1cS93 is involved in gene silencing in senescent cells in vivo.
To further investigate whether HP1c phosphorylation functionally is relative to cellular senescence, HP1c mutants (S93A, S93E, or S93W) were ectopically expressed in 2BS fibroblasts, while shHP1c was used to deplete endogenous HP1c. HP1c or mutant HP1c (S93E) overexpression, without RasV12, did not induce SAHF or senescent phenotype (data not shown). RasV12-induced senescence was delayed by S93A mutant, but not S93E mutant or S93W HP1c (Fig. 4F) ; this indicates that it is phosphorylated HP1c that is associated with cells proliferation arrest.
IL-6 signaling regulates PIM-1 expression during OIS
Having identified PIM-1 as an important regulator of cellular senescence, we continued on to resolve the mechanism underlying the up-regulation of PIM-1 expression during senescence. Previous reports have shown that PIM-1 gene expression is induced by a large set of cytokines (Bachmann & Moroy, 2005) , and many cytokine genes, including IL-6 and IL-8, are activated during senescence (Coppe et al., 2008) . Thus, we reasoned that cytokine signaling is critically involved in the regulation of PIM-1 in senescent cells. Here, we chose to study IL-6 and IL-8, because these cytokines play a critical role in cellular senescence (Acosta et al., 2008; Kuilman et al., 2008) . Dynamic analysis revealed that IL-6 and IL-8 expression coincided with the induction of PIM-1 expression (Fig. 5A) . Subsequently, we determined whether depletion of each of these cytokines blocks the RasV12-induced PIM-1 expression. IL-6 knockdown with a validated shRNA evidently attenuated the RasV12 induction of PIM-1 expression, whereas shRNA against IL-8 had little, if any, effect on PIM-1 expression, suggesting that IL-6 is associated with PIM-1 expression in OIS (Fig. 5B) . Figure 5(C) showed that IL-6 and IL-8 were effectively knocked down by their specific shRNA. The PIM-1 promoter contains a perfect consensus binding site from À793 to À758 bp for the transcription factor, STAT3, a downstream effecter of IL-6. To examine whether the IL-6/STAT3 pathway directly regulates PIM-1 expression at the transcriptional level, this binding site was mutated from GTTCCAGGC to GGAGAAGGC. Reporter analysis showed that RasV12 overexpression increased the wild-type PIM-1 promoter activity, and mutation of the STAT3 binding site dramatically attenuated the RasV12-induced promoter activity (Fig. 5D ). In addition, expressing IL-6 shRNA suppresses the PIM-1 promoter activity (Fig. 5E ). These data suggest that the IL-6/STAT3 pathway activates the transcription of PIM-1 gene. Subsequently, we determined whether STAT3 is activated as a function of oncogenic stress. Indeed, STAT3 phosphorylation at Tyr705, which is a marker of STAT3 activation, increased during OIS (Fig. 5F ). An EMSA experiment also identified that the STAT3 (but not STAT1) DNA-binding capacity increased during OIS (Fig. 5G) . ChIP assay was performed to confirm that STAT3 binds to the PIM-1 promoter in living cells. As expected, STAT3 bound to the PIM-1 promoter in vivo upon exposure of oncogenic stress (Fig. 5H) . Depletion of STAT3 or IL-6 with shRNA strongly diminished this binding, further validating the specificity of this signaling pathway (Fig. 5H) . Taken together, these data suggest that activation of IL-6/STAT3 signaling upregulates PIM-1 expression during OIS.
Our data above raised the possibility that IL-6/STAT3 signaling has an essential role in DNA damage response and heterochromatin formation. Indeed, shRNA that successfully targeted IL-6 or STAT3 led to lower levels of cH2AX and pHP1cS93 expression (Fig. 6A ) and decreased HP1c foci formation upon oncogenic stress (Fig. 6B) . It suggests that IL-6/ STAT3 signaling functionally is associated with PIM-1 at least in OIS. To further explore whether PIM-1 and IL-6/STAT3 act epistatically, we analyzed the effects of shPIM-1/shIL-6, shPIM-1/shSTAT3, shPIM-1, shIL-6, or shSTAT3 on RasV12-induced senescence. Results showed that cells with shPIM-1/shIL-6 or shPIM-1/shSTAT3 co-expression displayed stronger proliferative capacity than cells with shPIM-1 alone, but no difference was observed between shPIM-1/shIL-6 or shPIM-1/shSTAT3 co-expression and shIL-6 or shSTAT3 alone (Fig. 6C) , suggesting that besides of PIM-1, other factors also involved in IL-6 regulation of cellular senescence.
PIM-1 expression is elevated in preneoplastic lesions
PIM-1 up-regulation during OIS prompted us to ask whether it might also be up-regulated in preneoplastic lesions associated with senescent cells. To this end, we monitored PIM-1 expression inhuman colon adenomas by immunohistochemical staining. We choose this lesion because it contains cell groups displaying two hallmarks of cellular senescence, strong p16
INK4A immunopositivity, and absence of both mitotic figures and Ki-67 (Dai et al., 2000) . As shown in Fig. 6D , preneoplastic colon adenomas were enriched in senescent cells, which were judged by p16 INK4A staining. Furthermore, these samples stain positive for PIM-1, suggesting that PIM-1 contributes to OIS in vivo.
Discussion
Proliferative arrest is a major characteristic of senescent cells. It is not difficult to understand why many anti-oncogenes are activated and exert a key role in cellular senescence. Increasing evidences have shown that cellular senescence acts as a protective mechanism against carcinogenesis (Lanigan et al., 2011; Hoenicke & Zender, 2012; Vargas et al., 2012) . Unexpectedly, in this study, we found that the oncogene PIM-1 expression is induced during senescence and loss of PIM-1 can impair the cellular senescence response in normal fibroblasts, suggesting that PIM-1 probably has properties of a tumor suppressive role. Through searching the oncomine database (http:/www.oncomine.org), we found that PIM-1 displays an under-expressed expression in some tumor tissue such as breast cancer, esophageal cancer and ovarian cancer (data not shown).
Other studies have reported that a high PIM-1 level correlates with good prognosis in prostate adenocarcinoma, pancreatic ductal carcinoma, and nonsmall cell lung cancer (Dhanasekaran et al., 2001; Reiser-Erkan et al., 2008; Warnecke-Eberz et al., 2008) . Another experiment supporting this view, although not relating to tumors, showed that PIM-1 plays a prodeath role in neurons exposed to DNA damage (Zhang et al., 2010) , which is contrary to its pro-survival properties of dividing cells. In this sense, PIM-1 itself is part of the cellular senescence mechanism. Inhibition of PIM-1 expression alone probably induces tumorigenesis in normal cells upon activation of other oncogenic stress. Thus, one must be cautious when selecting PIM-1 inhibitor for cancer therapeutic intervention. Our current study characterized that PIM-1 phosphorylates HP1c on Ser93, and this modification promotes HP1c to bind to H3K9m3 for heterochromatin formation in OIS. However, the same site, previous referred as Ser83 due to splicing variant, can also be phosphorylated by protein kinase A (PKA) in cancer cell lines (Lomberk et al., 2006) . Lomberk et al. reported that p-Ser83-HP1c has an exclusively euchromatic localization, impairs silencing activity, and serves as a marker for transcription elongation. These contradictory results raise the possibility that Ser93 phosphorylation may influence HP1c localization and function through different combinations of other post-translational modifications. It has been shown that Thr51, located at the N-terminal chromodomain (CD) of HP1b, can be phosphorylated by CK2 and can reduce the affinity of HP1b for H3K9me3 binding (Ayoub et al., 2008) . Given that CD is a highly conserved domain among the three HP1 isoforms and CK2 activity is decreased in senescent cells (Ryu et al., 2006) , the absence of Thr51 phosphorylation may be conducive to pHP1cS93 binding to H3K9me3 and heterochromatin formation during senescence. In contrast, cancer cells have high CK2 activity (Hanif et al., 2010; Trembley et al., 2010) . Hence, Thr51 phosphorylation may block pHP1cS93 binding to the chromatin via H3K9me3, shifting the HP1c function from heterochromatin formation and gene silencing to euchromatic gene expression. Of course, other mechanisms regulating the localization of pHP1cS93 cannot be ruled out.
It has been shown that OIS is specifically linked to the activation of an inflammatory transcriptome, including pleiotropic cytokine IL-6 (Coppe et al., 2008) . Besides its paracrine mitogenic action, IL-6 is required for the execution of OIS in a cell-autonomous mode (Kuilman et al., 2008) . IL-6 depletion causes the inflammatory network to collapse and abolishes senescence entry and maintenance (Kuilman et al., 2008) . Several pathways have been shown to contribute to the induction of IL-6 during OIS (Kuilman et al., 2008; Rodier et al., 2009; Chien et al., 2011) ; however, the mechanisms by which IL-6 regulates OIS have not been studied. In the current study, we demonstrated that IL-6 signaling might regulate DNA damage response and heterochromatin formation, which plays an important role in the induction and maintenance of cellular senescence respectively, at least partly through induction of PIM-1 expression. Interestingly, neither IL6 nor PIM1 knockdown can affect cell senescence or SAHF formation by itself without stress from RasV12. Kuilman et al. have also showed that IL-6 activated senescence by induction of p15-INK4b. Here, we observed an increased IL-6 level after overexpression of PIM-1 (Fig. 2E) , which suggested an indirectly regulation between PIM-1 and p15 during cell senescence.
It is widely accepted that chromatin near a damaged site requires an 'opened' state for efficient recruitment of repair factors and subsequent repair (Price & D'Andrea, 2013) . Thus, heterochromatin formation during senescence most likely prevents DNA repair factors from approaching damaged DNA sites, resulting in a persistent DNA damage response (DDR). It has been shown that DDR signaling triggers senescence-associated inflammatory cytokine secretion including IL-6 (Rodier et al., 2009) . In prostate cancer cell lines, PIM1 was able to induce senescence, which is associated with DNA damage and activation of the p53 pathway (Zemskova et al., 2010) . It is conceivable that IL-6 up-regulation promotes heterochromatin formation and thus leads to sustained DDR. This positive feedback loop between DNA damage response and IL-6, which is involved in heterochromatin, possibly plays a critical role in the maintenance of cellular senescence.
SAHF are thought to contribute to the irreversible cell cycle exit in many senescent cells by repressing the expression of proliferationpromoting gene such as CCNA2. Several proteins take part in the formation and/or maintenance of the SAHF, including histone chaperones HIRA and Asf1, HP1 and high-mobility group A (HMGA) proteins, histone variant macroH2A, and Rb. It has been shown that in cells entering senescence, HP1c, but not the related proteins HP1a and HP1b, become phosphorylated on serine 93, and this phosphorylation is required for efficient incorporation of HP1c into SAHF. We identified that kinase PIM-1 is responsible for this phosphorylation of HP1c, and this modification is required for heterochromatin formation and silence of genes. However, it appears that this modification is not required for SAHF formation, because mutant HP1cS93E overexpression did not induce SAHF (data not shown), consisting with a previous report, which shows that reduction in the amount of HP1 proteins does not detectably affect chromosome condensation into SAHF. Thus, although PIM-1 knockdown suppresses SAHF formation, such effect likely is independent of HP1c.
Experimental procedures Cell culture and human samples
Human diploid fibroblasts 2BS and BJ cells were obtained from the National Institute of Biological Products, Beijing, China, and WI-38 cells were purchased from ATCC. Cells were cultured as described previously (de Zhuo et al., 2010) . Paraffin-embedded grade-II tubulovillous colon adenoma (n = 3) and adjacent normal tissues (n = 3) specimens were collected at Peking University First Hospital.
RNA interference
PIM-1, IL-6, IL-8, or STAT3 shRNAs were synthesized and cloned into pLVX-shRNA2 vector (Clontech, Mountain View, CA, USA). The resulting plasmids were used for generating lentiviruses. The sense strand of various shRNAs was available in Table S1 . To produce shRNA lentivirus for target cells infection, the pLVX-shRNA plasmid was transfected into 293T packaging cells using the Lenti-X HTX Packaging System (Clontech). Virus-containing medium was collected, supplemented with 8 lg mL À1 of polybrene (Sigma, St. Louis, MO, USA), and incubated with target 2BS cells at 37°C for 22 h. Infected cells were purified by drug selection (3 lg mL À1 puromycin).
Cell proliferation assay
Cells were infected with shRNA-expressing lentivirus, briefly selected for successful proviral integration. 4 9 10 5 cells with shRNA were seeded into 6-cm dish and subsequently infected with RasV12-encoding virus and selected. Cells were fixed and stained 10 days postselection with crystal violet.
Luciferase assay
The PIM-1 promoter was cloned via PCR in pGL3-Basic reporter vector (Promega, Madison, WI, USA). The oligonucleotide sequences for PCR primers were listed in Table S1 . The mutated PIM-1 promoter was constructed by the QuikChange site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA). For promoter activity assays, 2BS cells were seeded in a 24-well plate (1 9 10 5 cells/well), incubated overnight in complete growth medium, and transfected with 0.45 lg of reporter plasmid and 0.05 lg of control reporter (pRL-CMV). After 24 h of incubation, cells were lysed in passive lysis buffer (Promega), and luciferase activity was measured using the luciferase assay system (Promega) with a luminometer (Lumat LB 9501; Berthold, Bad Wildbad, Germany). All luciferase assays were conducted at least three times in triplicate. Firefly luciferase activity was normalized to the Renilla luciferase activity for each transfected well.
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was performed on cDNA generated from total RNA using the protocol of the M-MLV Reverse Transcriptase kit (Invitrogen, Carlsbad, CA, USA). Amplification and detection of specific products were performed with the ABI Prism 7300 sequence detection system (Invitrogen) with the cycle profile according to the TOYOBO SYBR qRT-PCR Mix kit (Osaka, Japan). Primer sequences are indicated in Table  S1 .
Immunoblotting
Western blot and immunoprecipitations were performed by standard method using the following antibodies: monoclonal mouse anti-human 
SA-b-gal, SAHF staining, and BrdU incorporation assay
SA-b-gal activity and SAHF staining were performed as described previously (de Zhuo et al., 2010) . For BrdU labeling, coverslips were transferred into a 6-well plate and incubated in 2 mL of the culture medium containing 10 lM BrdU for 36 h. The cells were then fixed with 4% paraformaldehyde for 10 min. Cells were incubated with 2 MHCl at 37°C for 20 min to denature the DNA. Neutralization of the DNA was conducted using Tris borate-EDTA buffer (pH 8.4). The cells were then blocked in Tris-buffered saline solution containing 1% bovine serum albumin and 0.1% triton X-100 for 1 h. Monoclonal antibody against BrdU (Sigma) was then added and incubated at 4°C overnight. Cells were incubated with horseradish peroxidase-conjugated secondary antibody for 30 min. A solution containing 3,3 0 -diaminobenzidine tetraanhydrochloride (0.16 mg mL À1 ) and 0.3% H 2 O 2 was then added and incubated for 30 min in the dark.
Chromatin immunoprecipitation and EMSA
Chromatin immunoprecipitation (ChIP) was performed using a chromatin immunoprecipitation assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Antibodies used for ChIP were anti-STAT3 (Cell Signaling) and antiphospho-HP1c. Primer pairs used for PCR were described in Table S1 . Electrophoretic mobility shift assays (EMSA) were performed using the Light Shift Chemiluminescent EMSA Kit (Thermo) and Biotin 3 0 End DNA Labeling Kit (Thermo). The oligonucleotide sequence of the DNA probe was described in Table S1 .
GST-HP1c fusion protein purification and in vitro phosphorylation assays
GST and GST-HP1c fusion protein expression was induced in BL21 cells (Stratagene) by the addition of 2 mM isopropyl-b-D-thiogalactopyranoside and incubation for 2 hr at 37°C. Cells were lysed and subsequently purified using glutathione Sepharose 4B affinity chromatography in accordance with the manufacture instructions. For in vitro phosphorylation assays, fusion proteins were incubated with recombinant kinase rPIM-1 (Abnova, Taipei, Taiwan) for 20 min at 22°C in buffer containing 25 mM HEPES-KOH, pH 7.5, 30 mM NaCl, 10 mM MgCl 2 , 0.5 mM dithiothreitol, and 10 lCi (3000 Ci mmol
À1
) of [c-32 P]ATP. The reaction mixture was boiled in Laemmli buffer, and phosphorylated proteins were separated by 12% SDS-PAGE followed by autoradiography.
H3K9me2 binding assays
H3K9me2-binding assays were carried out with biotinylated H3K9me2 peptide (Upstate Biotechnologies, Lake Placid, NY, USA; 12-404) attached to streptavidin agarose beads (Pierce, Rockford, IL, USA; 20347). Binding assays were carried out with 4 nmol H3K9me2 peptide and 2 lg bacterially expressed recombinant GST-HP1c protein (or its S93A mutant form), and 20 lL of 50% streptavidin agarose beads was added to a PBS-based-binding buffer containing 0.2% NP-40 and 0.1% BSA and incubated at room temperature for 1 h. For phosphorylation assay, a 25 lL kinase reaction contains 2 lg GST-HP1 proteins, and 1 lg rPIM-1 in PIM-1 buffer with 10 lM ATP . After binding, the mixture was centrifuged at 5000 g for 10 min, and all supernatant removed by gentle aspiration. GST-HP1c pull-down by the agarose beads was detected by western blot with HP1c antibody and was used to judge the binding of HP1c to H3K9me2.
Immunofluorescence
Cells fixed with 4% formaldehyde were incubated with phosphatebuffered saline containing 0.1% triton X-100 and 2% bovine serum albumin for 1 h at room temperature, followed by incubation with antibodies specific for HP1c (1:500; Santa Cruz) and H3K9me3 (1:500; CST) overnight at 4°C. Cells were then washed with phosphatebuffered saline plus 0.1% triton X-100 and incubated with a fluorophore-conjugated secondary antibody. Cells were imaged on a Zeiss LSM 410 confocal laser-scanning microscope with 960 magnification.
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